Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijid.2021.01.055 http://scihub22266oqcxt.onion/10.1016/j.ijid.2021.01.055 33515771!7840408!33515771     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Infect+Dis 2021 ; 104 (ä): 641-648 Nephropedia Template TP {{tp|p=33515771|t=2021. Efficacy of ribavirin and interferon-alpha therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study |pdf=|usr=}}{{33515771}} gab.com Text Efficacy of ribavirin and interferon-alpha therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study JO: Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33515771 #FOAvip OBJECTIVE: To assess the efficacy and safety of ribavirin and interferon-alpha (RBV/IFN-alpha) therapy in COVID-19 patients. METHODS: A multicenter, retrospective cohort study of COVID-19 patients admitted to 4 hospitals in Hubei Province, China, from 31 December 2019 to 31 March 2020. Patients were divided into 2 groups according to their exposure to RBV/IFN-alpha therapy within 48 h of admission. Mixed-effect Cox model and Logistic regression were used to explore the association between early treatments of RBV/IFN-alpha and primary outcomes. RESULTS: Of 2037 patients included, 1281 received RBV/IFN-alpha (RBV, IFN-alpha or RBV combined with IFN-alpha) treatments and 756 received none of these treatments. In a mixed effect model, RBV/IFN-alpha therapy was not associated with progression from non-severe into severe type (adjusted hazard ratio (aHR) = 1.09, 95% CI: 0.88-1.36) or with reduction in 30-day mortality (aHR = 0.89, 95% CI: 0.61-1.30). However, it was associated with a higher probability of hospital stay >15 days (adjusted odds ratio (aOR) = 2.11, 95% CI: 1.68-2.64) compared with no RBV/IFN-alpha therapy. The propensity score-matched cohort and subgroup analysis displayed similar results. CONCLUSION: RBV/IFN-alpha therapy was not observed to improve clinical outcomes in COVID-19 patients suggesting that RBV/IFN-alpha therapy should be avoided in COVID-19 treatment. Twit Text FOAVip Efficacy of ribavirin and interferon-alpha therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study ????Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33515771 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33515771 #FOAvip English Wikipedia <ref>{{Cite pmid|33515771}}</ref> Efficacy of ribavirin and interferon-alpha therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study #MMPMID33515771 Li H; Xiong N; Li C; Gong Y; Liu L; Yang H; Tan X; Jiang N; Zong Q; Wang J; Lu Z; Yin X Int J Infect Dis 2021[Mar]; 104 (ä): 641-648 PMID33515771show ga OBJECTIVE: To assess the efficacy and safety of ribavirin and interferon-alpha (RBV/IFN-alpha) therapy in COVID-19 patients. METHODS: A multicenter, retrospective cohort study of COVID-19 patients admitted to 4 hospitals in Hubei Province, China, from 31 December 2019 to 31 March 2020. Patients were divided into 2 groups according to their exposure to RBV/IFN-alpha therapy within 48 h of admission. Mixed-effect Cox model and Logistic regression were used to explore the association between early treatments of RBV/IFN-alpha and primary outcomes. RESULTS: Of 2037 patients included, 1281 received RBV/IFN-alpha (RBV, IFN-alpha or RBV combined with IFN-alpha) treatments and 756 received none of these treatments. In a mixed effect model, RBV/IFN-alpha therapy was not associated with progression from non-severe into severe type (adjusted hazard ratio (aHR) = 1.09, 95% CI: 0.88-1.36) or with reduction in 30-day mortality (aHR = 0.89, 95% CI: 0.61-1.30). However, it was associated with a higher probability of hospital stay >15 days (adjusted odds ratio (aOR) = 2.11, 95% CI: 1.68-2.64) compared with no RBV/IFN-alpha therapy. The propensity score-matched cohort and subgroup analysis displayed similar results. CONCLUSION: RBV/IFN-alpha therapy was not observed to improve clinical outcomes in COVID-19 patients suggesting that RBV/IFN-alpha therapy should be avoided in COVID-19 treatment. |*COVID-19 Drug Treatment[MESH] |*SARS-CoV-2[MESH] |Adult[MESH] |Aged[MESH] |Antiviral Agents/*administration & dosage[MESH] |COVID-19/mortality[MESH] |Drug Therapy, Combination[MESH] |Female[MESH] |Humans[MESH] |Interferon-alpha/*administration & dosage[MESH] |Male[MESH] |Middle Aged[MESH] |Retrospective Studies[MESH]Efficacy of ribavirin and interferon-alpha therapy for hospitalized pa(epmc).pdf DeepDyve Pubget Overpricing